Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

United Therapeutics (UTHR) Shares Outstanding (2016 - 2026)

United Therapeutics' Shares Outstanding history spans 17 years, with the latest figure at $76.5 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 1.94% to $76.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $76.5 million, a 1.94% increase, with the full-year FY2025 number at $76.5 million, up 1.94% from a year prior.
  • Shares Outstanding hit $76.5 million in Q4 2025 for United Therapeutics, up from $42.9 million in the prior quarter.
  • Over the last five years, Shares Outstanding for UTHR hit a ceiling of $76.5 million in Q4 2025 and a floor of $42.9 million in Q3 2025.
  • Historically, Shares Outstanding has averaged $71.9 million across 5 years, with a median of $73.4 million in 2023.
  • Biggest five-year swings in Shares Outstanding: rose 1.95% in 2023 and later crashed 42.64% in 2025.
  • Tracing UTHR's Shares Outstanding over 5 years: stood at $71.7 million in 2021, then grew by 1.39% to $72.7 million in 2022, then increased by 1.38% to $73.7 million in 2023, then grew by 1.76% to $75.0 million in 2024, then grew by 1.94% to $76.5 million in 2025.
  • Business Quant data shows Shares Outstanding for UTHR at $76.5 million in Q4 2025, $42.9 million in Q3 2025, and $75.4 million in Q2 2025.